BioXcel Therapeutics (BTAI) Reports Q1 Loss of $1.08/sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
BioXcel Therapeutics (BTAI) PT Raised to $128 at Truist Securities
May 10, 2021 12:13 PM EDTTruist Securities analyst Robyn Karnauskas raised the price target on BioXcel Therapeutics (NASDAQ: BTAI) to $128.00 (from $127.00) while maintaining a Buy rating.
The analyst commented, "Key 1Q21 takeaways: 1) commercial US prep on track for '501 key indications launching 1Q22; 2) '501 EU market may provide... More
